Clinical trials: Hay Fever
Rhinitis, Allergic, Seasonal
Study of AHIST in Seasonal Allergic Rhinitis Patients
Objectives: A) To gather pharmacodynamic measurements and assess blood levels of the active ingredients in AHIST over the dosage interval period of 12 hours.
- Trial name
- NCT01008397
- Testing
- AHIST NDC#58407-012-01
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Magna Pharmaceuticals, Inc.
Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)
This is an 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612820
- Testing
- GSK256066, fluticasone propionate
- Where
- Austria
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hayfever
Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen
This is a placebo controlled double-blind single center study initiated and sponsored by CALPIS, Inc., Japan, and CALPIS U.S.A., Inc., Torrance, CA.
- Trial name
- NCT00554736
- Testing
- Lactobacillus acidophilus L-92
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Davis
Anaphylaxis
Bioavailability of Nasal Epinephrine
A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder with Epinephrine 0.3 mg Intramuscular Injection in Adult Subjects with Seasonal Allergic Rhinitis with and…
- Trial name
- NCT04696822
- Testing
- Epinephrine Nasal Product, 1.6 mg, Epinephrine nasal product, 1.6 mg + allergen, Epinephrine Injection 0.3 mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Allergic Rhinitis
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
- Trial name
- NCT00929968
- Testing
- VAK694, Fluticasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals